| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Lisa McClain MI09 | 3 | 3 | +$0 | Sold Oct 31, 25 |
| Jefferson Shreve IN06 | 1 | −$32.5K | Sold Apr 7, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Oct 31, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Nov 21, 25 (21d) | |
| Oct 30, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Nov 21, 25 (22d) | |
| Oct 30, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Nov 21, 25 (22d) | |
| Jul 22, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (22d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Sell (part) | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| Jun 11, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (63d) | |
| Apr 7, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | May 8, 25 (31d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Douglass Brian RobbOfficer | Stock Award(Grant) at price 0.00 per share. | 700 | — |
| Oct 4, 2026 | Loeillot OlivierChief Executive Officer | Conversion of Exercise of derivative security at price 154.96 per share. | 4.2K | $651.14K |
| Oct 4, 2026 | Loeillot OlivierChief Executive Officer | Sale at price 178.75 - 190.00 per share. | 5.5K | $1.04M |
| Sep 20, 2026 | Loeillot OlivierChief Executive Officer | Conversion of Exercise of derivative security at price 141.79 per share. | 5.4K | $769.35K |
| Sep 20, 2026 | Loeillot OlivierChief Executive Officer | Sale at price 180.00 per share. | 5.4K | $976.68K |
| Sep 3, 2026 | Loeillot OlivierChief Executive Officer | Sale at price 165.90 per share. | 3K | $503.51K |
| Aug 19, 2026 | Loeillot OlivierChief Executive Officer | Conversion of Exercise of derivative security at price 141.79 per share. | 5.4K | $769.35K |
| Aug 19, 2026 | Loeillot OlivierChief Executive Officer | Sale at price 180.00 per share. | 5.4K | $976.68K |
| Jul 15, 2026 | Garland Jason K.Chief Financial Officer | Sale at price 150.00 per share. | 530 | $79.50K |
| Jun 24, 2026 | Garland Jason K.Chief Financial Officer | Sale at price 145.00 per share. | 733 | $106.28K |
| May 13, 2026 | Eglinton Manner CarrieDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Mhatre RohinDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Konstantinov Konstantin BDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Pax MargaretDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Dawes Karen ADirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Barthelemy Nicolas MDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Madaus Martin D Ph.D.Director | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 13, 2026 | Muir Glenn PDirector | Stock Award(Grant) at price 0.00 per share. | 995 | — |
| May 6, 2026 | Muir Glenn PDirector | Conversion of Exercise of derivative security at price 38.76 per share. | 2.4K | $94.34K |
| Apr 20, 2026 | Loeillot OlivierChief Executive Officer | Sale at price 140.00 per share. | 3.8K | $536.48K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.8 | -13.8 | -8.5 | 0.4 | 4.8 | 10.1 | 3.3 | 28.3 | 6.2 | -10.3 | +5.3% | ||
| 2025 | 15.5 | -4.2 | -20.1 | 8.4 | -14.4 | 5.3 | -5.9 | 4.5 | 9.3 | 11.5 | 14.7 | -4.2 | +13.8% |
| 2024 | 5.3 | 2.4 | -5.2 | -10.7 | -9.2 | -15.4 | 32.8 | -9.8 | -1.4 | -9.8 | 12.1 | -4.4 | −19.9% |
| 2023 | 9.4 | -5.9 | -3.4 | -9.9 | 10.7 | -15.8 | 21.3 | 1.4 | -8.6 | -15.4 | 16.9 | 14.3 | +6.2% |
| 2022 | -25.1 | -0.8 | -4.4 | -16.4 | 4.6 | -1.3 | 31.4 | 2.8 | -14.7 | -2.5 | -2.0 | -5.3 | −36.1% |
| 2021 | 4.4 | 6.2 | -8.5 | 8.9 | -13.7 | 9.3 | 23.1 | 15.2 | 2.1 | 0.5 | -1.4 | -7.6 | +38.2% |
| 2020 | 8.5 | -14.7 | 12.8 | 20.3 | 12.8 | -5.6 | 22.1 | 2.7 | -4.8 | 12.9 | 13.9 | 1.0 | +107.2% |
| 2019 | 8.1 | 4.4 | -0.7 | 14.0 | 3.1 | 23.7 | 9.8 | -1.7 | -17.4 | 3.7 | 11.6 | 4.2 | +75.4% |
| 2018 | -2.5 | -3.1 | 5.5 | 2.3 | 18.1 | 7.7 | 2.7 | 13.6 | 1.1 | -2.2 | 19.3 | -18.4 | +45.4% |
| 2017 | -2.5 | 4.9 | 11.7 | 4.5 | 6.7 | 5.6 | -2.8 | 8.4 | -12.3 | -2.9 | -4.7 | 2.3 | +17.7% |
| 2016 | -21.7 | 16.2 | 4.2 | -0.7 | -10.1 | 14.2 | 4.5 | 8.4 | -2.6 | -5.4 | 12.7 | -4.3 | +8.9% |
| 2015 | 22.7 | 5.8 | 18.1 | -2.8 | 38.1 | 1.3 | -15.2 | -2.7 | -18.3 | 19.4 | -14.5 | -0.5 | +42.9% |
| 2014 | 13.5 | -3.3 | -14.1 | 23.3 | 21.4 | 18.5 | -8.0 | -9.1 | 4.5 | 26.7 | -9.3 | -13.4 | +45.2% |
| 2013 | 9.9 | -9.7 | 10.9 | 29.7 | -7.6 | -0.5 | 23.4 | -4.0 | 13.6 | -1.4 | 23.1 | 1.3 | +117.2% |
| 2012 | 15.6 | 10.0 | 33.8 | -25.3 | -7.3 | 5.1 | -6.5 | 41.5 | 4.7 | -14.4 | 26.5 | -2.6 | +81.0% |
| 2011 | 10.2 | -6.8 | -22.4 | 7.0 | -4.8 | -4.5 | -3.0 | -6.2 | -1.5 | 5.2 | -1.5 | 2.7 | −26.0% |
| 2010 | -16.1 | -2.3 | 20.5 | -13.5 | 1.1 | -9.6 | 0.6 | 5.0 | -0.3 | 14.8 | -4.1 | 26.1 | +14.1% |
| 2009 | 8.2 | -4.4 | 22.5 | -11.3 | -4.2 | 35.1 | -2.4 | -6.5 | -0.2 | -2.6 | -3.7 | -12.6 | +8.7% |
| 2008 | -1.4 | -18.1 | -8.9 | 15.1 | 4.0 | -18.2 | 12.9 | 0.8 | -12.3 | -14.9 | -2.7 | -3.1 | −42.3% |
| 2007 | 12.1 | -1.6 | 1.9 | 11.1 | 10.3 | 0.8 | -1.3 | 12.2 | 0.2 | -1.8 | 12.5 | 37.0 | +133.1% |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Buy / hold / sell counts